The global AI in drug discovery market is experiencing steady growth, driven by the rising pressure on pharmaceutical companies to reduce time and cost of launching new drugs in market. The conventional methods of lead / hit identification require a lot of investment, in terms of time and resources.
Therefore, researchers are using machine learning systems that can rapidly screen a wide range of chemical and biological datasets to identify promising candidates earlier in the process. Such platforms help researchers to improve target identification, predict molecular interactions, and optimize leads with greater precision than conventional approaches.
Despite this progress, challenges such as limited access to high-quality data, the need for clearer regulatory guidance, and the difficulty of integrating AI tools into existing research workflows continue to slow broader adoption. To address these issues, developers are investing in more robust validation methods, signing partnerships with academic labs, and building platforms for pharmaceutical R&D pipelines.
Further, with rising interest in precision medicine, AI is expected to play a critical role in tailoring therapies to patient subpopulations using genomic, proteomic, and real-world data. As a result, the AI in drug discovery market is projected to experience robust growth in the coming years
According to Roots Analysis, "The AI in drug discovery market size is anticipated to be worth USD 8.6 billion in 2026 and this value is likely to reach around USD 25.0 billion by 2035, expanding at a CAGR of 12.6%"
Key Report Takeaways:
- More than 260 companies are currently active in offering AI-based drug discovery platforms, and close to 60% of them are based in North America
- Around 75% of the players apply their AI platforms mainly to advance their own in-house pipeline candidates, underscoring how pharmaceutical firms are steadily embedding AI tools to speed up discovery work
- Partnership activity has shown consistent growth in recent quarters, with research and development agreements standing out as the most common collaboration model in the AI drug discovery space
- Attracted by the strong potential of this market, investors have poured nearly USD 10.5 billion into the sector over the past two years
- Patent filings have risen sharply at a CAGR of 67% between 2021 and 2025, reflecting the demand for more efficient platforms that can shorten drug discovery timelines
- The cost-saving benefits of applying AI solutions across different therapeutic areas, particularly oncology, are expected to become even more substantial in the years ahead
- With ongoing research efforts, rising investment levels, and upcoming patent expirations, the AI in drug discovery market is positioned for steady expansion going forward
- The market is projected to expand at a CAGR of 12.6%, driven by the urgent need to lower R&D costs and timelines along with the growing use of machine learning for molecular screening
AI in Drug Discovery Market Key Players
- BenevolentAI
- Collaborations Pharmaceuticals
- CytoReason
- Deargen
- Deep Genomics
- Genialis
- Healx
- Insilico Medicine
- Iktos
- Optibrium
- XtalPi
You Can Download Free Sample PDF Copy of This Report At: https://www.rootsanalysis.com/reports/ai-based-drug-discovery-market/request-sample.html
